Cancer Biomarkers Market, by Biomarker Type (Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer and Other Cancers), by End User (Hospitals, Academic

Cancer Biomarkers Market, by Biomarker Type (Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer and Other Cancers), by End User (Hospitals, Academic and Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories) - Global Industry Insights, and Forecast, 2022 - 2028

Report Description
Cancer biomarkers offers great opportunity in improving management of cancer patients by enhancing the efficiency of detection and efficacy of the treatment. Biomarkers of cancer includes various biochemical components such as proteins, sugars, lipids, nucleic acids, and small metabolites, cytogenetic and cytokinetic parameters, and whole tumor cells, which are found in body fluid. Increasing research and development activities in the field of cancer biomarker to develop and identify potential cancer biomarkers for early diagnosis of cancer, will lead to the growth of cancer biomarkers market, in the near future. For instance, in March 2018, a team of researchers from University of Massachusetts and Clarkson University discovered various protein such as human chorionic gonadotropin (hCG), lipoproteins, α1-chymotrypsin and α1-antitrypsin from breast milk, which can act as a potential cancer biomarker in detection of breast cancer.
Market Dynamics
The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies. For instance, according to the Cancer Atlas: 2017, there were an estimated 14.1 million new cancer cases in 2012. Moreover, India, China and other East and Central Asian countries accounted for nearly half of world’s new cancer cases and deaths, in 2017. Furthermore, according to the same source, by 2025, there will be an estimated 19.3 million new cancer cases and 11.4 million cancer deaths, in emerging economies. However, high cancer treatment cost and unfavorable reimbursement policies for cancer biomarker may hinder the growth of cancer biomarkers market.
Key features of the study:
This report provides in-depth analysis of the cancer biomarkers market and its market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global cancer biomarkers market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
Key companies covered as a part of this study include BioMerieux S.A., Bard1 Life Sciences Limited, Bio-Rad Laboratories, Abbott Laboratories, Becton, Dickinson and Company, Merck & Co., Inc., Qiagen N.V., and Thermo Fisher Scientific Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion and marketing tactics.
The global cancer biomarkers market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for cancer biomarkers market, research and consulting firms, new entrants and financial analysts.

Detailed Segmentation:
Global Cancer Biomarkers Market, By Biomarker Type:
Protein Biomarkers
Genetic Biomarkers
Other Cancer Biomarkers
Global Cancer Biomarkers Market, By Cancer Type:
Breast Cancer
Lung Cancer
Prostate Cancer
Kidney Cancer
Liver Cancer
Other Cancers
Global Cancer Biomarkers Market, By End User:
Hospitals
Academic and Cancer Research Institutes
Ambulatory Surgical Centers
Cancer Diagnostic Laboratories
Global Cancer Biomarkers Market, By Region:
North America
By Country:
U.S.
Canada
By Biomarker Type:
Protein Biomarkers
Genetic Biomarkers
Other Cancer Biomarkers
By Cancer Type:
Breast Cancer
Lung Cancer
Prostate Cancer
Kidney Cancer
Liver Cancer
Other Cancers
By End User:
Hospitals
Academic and Cancer Research Institutes
Ambulatory Surgical Centers
Cancer Diagnostic Laboratories
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Biomarker Type:
Protein Biomarkers
Genetic Biomarkers
Other Cancer Biomarkers
By Cancer Type:
Breast Cancer
Lung Cancer
Prostate Cancer
Kidney Cancer
Liver Cancer
Other Cancers
By End User:
Hospitals
Academic and Cancer Research Institutes
Ambulatory Surgical Centers
Cancer Diagnostic Laboratories
Asia Pacific
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
By Biomarker Type:
Protein Biomarkers
Genetic Biomarkers
Other Cancer Biomarkers
By Cancer Type:
Breast Cancer
Lung Cancer
Prostate Cancer
Kidney Cancer
Liver Cancer
Other Cancers
By End User:
Hospitals
Academic and Cancer Research Institutes
Ambulatory Surgical Centers
Cancer Diagnostic Laboratories
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Biomarker Type:
Protein Biomarkers
Genetic Biomarkers
Other Cancer Biomarkers
By Cancer Type:
Breast Cancer
Lung Cancer
Prostate Cancer
Kidney Cancer
Liver Cancer
Other Cancers
By End User:
Hospitals
Academic and Cancer Research Institutes
Ambulatory Surgical Centers
Cancer Diagnostic Laboratories
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Biomarker Type:
Protein Biomarkers
Genetic Biomarkers
Other Cancer Biomarkers
By Cancer Type:
Breast Cancer
Lung Cancer
Prostate Cancer
Kidney Cancer
Liver Cancer
Other Cancers
By End User:
Hospitals
Academic and Cancer Research Institutes
Ambulatory Surgical Centers
Cancer Diagnostic Laboratories
Africa
By Country:
North Africa
Central Africa
South Africa
By Biomarker Type:
Protein Biomarkers
Genetic Biomarkers
Other Cancer Biomarkers
By Cancer Type:
Breast Cancer
Lung Cancer
Prostate Cancer
Kidney Cancer
Liver Cancer
Other Cancers
By End User:
Hospitals
Academic and Cancer Research Institutes
Ambulatory Surgical Centers
Cancer Diagnostic Laboratories
Company Profiles
BioMerieux S.A. *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Bard1 Life Sciences Limited
Bio-Rad Laboratories
Abbott Laboratories
Becton, Dickinson and Company
Merck & Co., Inc.
Qiagen N.V.
Thermo Fisher Scientific Inc.
“*” marked represents similar segmentation in other categories in the respective section.